Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
Arch Pharm Res
; 43(8): 765-772, 2020 Aug.
Article
in English
| MEDLINE | ID: covidwho-692878
ABSTRACT
A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Chloroquine
/
Coronavirus Infections
/
Hydroxychloroquine
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Arch Pharm Res
Year:
2020
Document Type:
Article
Affiliation country:
S12272-020-01258-7
Similar
MEDLINE
...
LILACS
LIS